BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34915036)

  • 1. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers.
    Liu Z; Lin C; Suo C; Zhao R; Jin L; Zhang T; Chen X
    Metabolism; 2022 Feb; 127():154955. PubMed ID: 34915036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
    Chen S; Pang J; Huang R; Xue H; Chen X
    Hepatol Int; 2023 Jun; 17(3):595-605. PubMed ID: 36809487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
    Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer.
    Wei S; Hao Y; Dong X; Huang J; Huang K; Xie Y; Liu H; Wei C; Xu J; Huang W; Dong L; Yang J
    Front Endocrinol (Lausanne); 2023; 14():985858. PubMed ID: 36891047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
    Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
    Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
    Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
    Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
    Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
    Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants.
    Liu Z; Suo C; Shi O; Lin C; Zhao R; Yuan H; Jin L; Zhang T; Chen X
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e855-e875. PubMed ID: 33387670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
    Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
    Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population.
    Lee Y; Cho EJ; Choe EK; Kwak MS; Yang JI; Oh SW; Yim JY; Chung GE
    Sci Rep; 2024 Apr; 14(1):9753. PubMed ID: 38679617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
    Wei S; Song J; Xie Y; Huang J; Yang J
    JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
    Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
    J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome.
    Liu CC; Huang SP; Lee YC; Lee CH; Huang TY; Geng JH; Chang CW; Lin CY; Juan YS; Wu WJ; Hsieh TJ
    Front Endocrinol (Lausanne); 2023; 14():1252774. PubMed ID: 37854195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
    Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
    Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between metabolic dysfunction-associated fatty liver disease and abdominal aortic aneurysm.
    Jia Y; Li Y; Yu J; Jiang W; Liu Y; Zeng R; Wan Z; Liao X; Li D; Zhao Q
    Nutr Metab Cardiovasc Dis; 2024 Apr; 34(4):953-962. PubMed ID: 38161123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
    Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
    Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.